21 November 2013 
EMA/CHMP/712673/2013   
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Procoralan 
ivabradine  
On 21 November 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a 
positive opinion recommending a variation to the terms of the marketing authorisation for the 
medicinal product Procoralan. The marketing authorisation holder for this medicinal product is Les 
Laboratoires Servier. They may request a re examination of the CHMP opinion, provided that they 
notify the European Medicines Agency in writing of their intention within 15 days of receipt of the 
opinion. 
The CHMP adopted a change to a contraindication as follows: 
“Pregnancy, lactation and women of child-bearing potential not using appropriate 
contraceptive measures (see section 4.6)” 
Detailed conditions for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after the variation to the 
marketing authorisation has been granted by the European Commission. 
For information, the full contraindications for Procoralan will be as follows2: 
- 
- 
- 
- 
- 
- 
- 
“Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 
 Resting heart rate below 60 beats per minute prior to treatment 
 Cardiogenic shock 
 Acute myocardial infarction 
 Severe hypotension (< 90/50 mmHg) 
 Severe hepatic insufficiency 
 Sick sinus syndrome 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 
within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion. 
2 The text in bold represents the new or the amended contraindication. 
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom 
Telephone  +44 (0)20 7418 8400  Facsimile +44 (0)20 7418 8613 
E-mail info@ema.europa.eu  Website www.ema.europa.eu 
An agency of the European Union   
© European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
                                                
- 
- 
- 
- 
- 
- 
 Sino-atrial block 
 Unstable or acute heart failure 
 Pacemaker dependent (heart rate imposed exclusively by the pacemaker) 
 Unstable angina 
 AV-block of 3rd degree 
 Combination with strong cytochrome P450 3A4 inhibitors such as azole antifungals 
(ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os,  
josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone (see  
sections 4.5 and 5.2) 
- 
 Pregnancy, lactation and women of child-bearing potential not using appropriate  
contraceptive measures (see section 4.6)” 
Procoralan 
EMA/CHMP/712673/2013 
Page 2/2 
 
 
 
 
 
 
